Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02135692
Registration number
NCT02135692
Ethics application status
Date submitted
8/05/2014
Date registered
12/05/2014
Titles & IDs
Public title
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
Query!
Scientific title
A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
Query!
Secondary ID [1]
0
0
2014-000314-54
Query!
Secondary ID [2]
0
0
201312
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Other - Mepolizumab
Treatment: Drugs - SOC
Experimental: Mepolizumab 100 mg - All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
Treatment: Other: Mepolizumab
Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
Treatment: Drugs: SOC
Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annualized Rate of On-treatment Exacerbations Per Year
Query!
Assessment method [1]
0
0
Exacerbations are defined as the worsening of asthma which requires use of systemic corticosteroids intravenous (IV) or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit. On-Treatment data between first dose date and earliest of Withdrawal date/last dose + 28 days was considered for analysis. Analysis of the number of exacerbations was performed using a negative binomial generalized linear model.
Query!
Timepoint [1]
0
0
Baseline (Week 0) to Week 172
Query!
Primary outcome [2]
0
0
Number of Participants With Any On-treatment Adverse Event (AE) or On-treatment Serious AE (SAE)
Query!
Assessment method [2]
0
0
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. On-treatment AEs and on-treatment SAEs are the events occurring on/after the first dose of open-label mepolizumab date and before/on last dose+28 days.
Query!
Timepoint [2]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [1]
0
0
Mean Change From Baseline in Asthma Control Questionnaire (ACQ)-5 On-treatment Score
Query!
Assessment method [1]
0
0
The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, shortness of breath, wheeze). The response options for all these questions consist of a 0 (no impairment/limitation) to 6 (total impairment/ limitation) scale. The overall ACQ score is calculated as the mean of the 5 questions and therefore ranges between 0 (totally controlled) and 6 (severely uncontrolled). Baseline was considered as the latest assessment prior to first dose of mepolizumab in this study. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value.
Query!
Timepoint [1]
0
0
Baseline (Week 0) to Week 168
Query!
Secondary outcome [2]
0
0
Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1
Query!
Assessment method [2]
0
0
FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry at Baseline and Weeks 24, 48, 72, 96, 120, 144 and 168. Spirometry was performed within 1 hour of the Baseline assessment. Baseline was considered as the latest assessment prior to first dose of mepolizumab in this study. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). Data between first dose date and earliest of Withdrawal date/last dose + 28 days considered on-treatment.
Query!
Timepoint [2]
0
0
Baseline (Week 0) to Week 168
Query!
Secondary outcome [3]
0
0
Number of Participants Withdrawn From the Study Due to Lack of Efficacy and Adverse Events
Query!
Assessment method [3]
0
0
AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Number of participants withdrawn due to lack of efficacy and adverse events from the study have been presented.
Query!
Timepoint [3]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [4]
0
0
Number of Participants Hospitalized Due to Adverse Events Including Asthma Exacerbations
Query!
Assessment method [4]
0
0
AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or all events of possible drug induced liver injury with hyperbilirubinemia. Number of participants requiring hospitalization due to an on-treatment serious adverse event including asthma exacerbations are presented. On-treatment SAEs are the events occurring on/after the first dose of mepolizumab date and before/on last dose of mepolizumab + 28 days.
Query!
Timepoint [4]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [5]
0
0
Number of Participants With AEs Including Both Systemic (Allergic and Non-allergic) and Local Site Reactions
Query!
Assessment method [5]
0
0
AEs were collected from the Baseline visit until the follow-up visit (Week 172). Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab. Number of participants with AEs including both systemic (i.e. allergic/immunoglobulin (Ig)E-mediated and non-allergic) and local site reactions have been presented.
Query!
Timepoint [5]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [6]
0
0
Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for 12-lead Electrocardiogram (ECG)
Query!
Assessment method [6]
0
0
Twelve-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. Baseline was considered as the latest assessment prior to first dose of mepolizumab in this study. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles)..
Query!
Timepoint [6]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [7]
0
0
Number of Participants With Maximum Change From Baseline in QTcB and QTcF Interval for ECG Assessed at Any Time Post Baseline
Query!
Assessment method [7]
0
0
Twelve-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. Baseline was considered as the latest assessment prior to first dose of mepolizumab in this study. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value. Participants with maximum change from Baseline were summarised at any time post Baseline for the following categories \<-60, \>=-60 to \<-30, \>=-30 to \<0, \>=0 to \<30, \>=30 to \<60 and \>=60. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial.
Query!
Timepoint [7]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [8]
0
0
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Query!
Assessment method [8]
0
0
Vital sign measurements including systolic blood pressure (SBP) and diastolic blood pressure (DBP) were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point. Baseline was considered as the latest assessment prior to first dose of mepolizumab in this study. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value.
Query!
Timepoint [8]
0
0
Baseline (Week 0) to Week 168
Query!
Secondary outcome [9]
0
0
Change From Baseline in Pulse Rate
Query!
Assessment method [9]
0
0
Vital sign measurements including pulse rate was done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point. Baseline was considered as the latest assessment prior to first dose of mepolizumab in this study. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value.
Query!
Timepoint [9]
0
0
Baseline (Week 0) to Week 168
Query!
Secondary outcome [10]
0
0
Number of Participants With Positive Anti-mepolizumab Binding Antibodies (ADA) and Neutralizing Antibodies (NAb)
Query!
Assessment method [10]
0
0
Blood samples were collected for the determination of ADA just prior to administration of mepolizumab. Samples that tested positive for anti-mepolizumab antibodies were further tested for the presence of NAb. The highest value post-Baseline visit are based on each participant's highest post-Baseline titer. NAb assay result was only presented for participants with positive ADA assay. Highest value post-Baseline would be positive for a participant who had both negative and positive post-Baseline results. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Query!
Timepoint [10]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [11]
0
0
Number of Participants With Potential Clinical Importance Values for Change From Baseline Relative to the Reference Range for Clinical Chemistry Parameters at Any Time Post-Baseline
Query!
Assessment method [11]
0
0
Blood samples were collected to assess clinical chemistry laboratory parameters. Number of participants with Potential Clinical Importance values for change from Baseline relative to the reference range at any time post-Baseline are presented. Any time post Baseline = all visits (including scheduled and unscheduled) post-Baseline. Participants are counted in the category that their value changes to (low, normal or high), unless there was no change in their category. If lab value category was unchanged, participants were recorded in the "To Normal or No Change" category. Alanine Aminotransferase=ALT. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
Query!
Timepoint [11]
0
0
Baseline (Week 0) to Week 172
Query!
Secondary outcome [12]
0
0
Number of Participants With Potential Clinical Importance Values for Change From Baseline Relative to the Reference Range for Hematology Parameters at Any Time Post-Baseline
Query!
Assessment method [12]
0
0
Blood samples were collected to assess hematology laboratory parameters. Number of participants with Potential Clinical Importance values for change from Baseline relative to the reference range at any time post-Baseline are presented. Any time post Baseline = all visits (including scheduled and unscheduled) post-Baseline. Participants are counted in the category that their value changes to (low, normal or high), unless there was no change in their category. If lab value category was unchanged, participants were recorded in the "To Normal or No Change" category.
Query!
Timepoint [12]
0
0
Baseline (Week 0) to Week 172
Query!
Eligibility
Key inclusion criteria
* Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.
* Male or Eligible Female Subjects: To be eligible for the study, females of child-bearing potential must commit to consistent and correct use of an acceptable method of birth control and for 4 months after the last study drug administration. A urine pregnancy test is required of all females of childbearing potential at the initial Baseline Visit (Visit 1).
* French Subjects Only: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
* MEA115661 Participation: Subjects must have completed Visit 14 of MEA115661.
* Current Anti-Asthma Therapy: The subject's asthma has been treated with an ICS controller medication for the last 8 months with fluticasone propionate (FP) >=500 mcg/day (or equivalent).
* Disease Severity: Subjects must be assessed as having life-threatening /serious debilitating asthma in order to enroll, as defined by the following: Subjects enrolled in MEA115588 must meet one of the following criteria: a) Subject has a history of at least one intubation during their lifetime; b) >=3 asthma exacerbations in the 12 months prior to screening for MEA115588; c) >=1 or more hospitalization for asthma exacerbation in the 12 months prior to screening for MEA115588. Subjects enrolled in MEA115575 must meet one of the following criteria: d) Subject has a history of at least one intubation during their lifetime; e) Their optimized dose at randomization in MEA115575 was >=10mg of prednisone; f) >=1 or more hospitalization for asthma exacerbation in the 12 months prior to screening for MEA115575.
* Clinical Benefit: Subjects must have experienced documented clinical benefit to enroll. Subjects must meet the following criteria demonstrating clinical benefit: Subjects enrolled in MEA115588 who received mepolizumab must meet all of the following criteria: a) Subject must have had a reduction in their exacerbation frequency by >=50% during MEA115588. The baseline for comparison is the total number of exacerbations reported in the 12 months prior to screening for MEA115588. b) The investigator response on the "Clinician-Rated Response to Therapy" questionnaire at Visit 10 was either: mildly improved, moderately improved or significantly improved. Subjects enrolled in MEA115588 who received placebo must meet all of the following criteria: c) Subject must have had a reduction in their exacerbation frequency by >=50% during the first 8 months of MEA115661. The baseline for comparison is the total number of exacerbations reported in the 12 months prior to screening for MEA115588; d) The investigator confirms that the subject demonstrated improvement during MEA115661. Subjects enrolled in MEA115575 who received mepolizumab must meet all of the following criteria: e) Subject must have reduced their oral corticosteroid dose by >=50% during MEA115575. The baseline for comparison is the subject's optimized oral corticosteroid (OCS) dose at randomization in MEA115575; f) The investigator response on the "Clinician-Rated Response to Therapy" questionnaire at Visit 9 was either: mildly improved, moderately improved or significantly improved. Subjects enrolled in MEA115575 who received placebo must meet all of the following criteria: g) Subject must have reduced their oral corticosteroid dose at randomization by >=50% in the first 6 months of MEA115661. The baseline for comparison is the subject's optimized OCS dose at randomization in MEA115575; h) The investigator confirms that the subject demonstrated improvement during MEA115661.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
* Health Status: Clinically significant change in health status during MEA115661 which in the opinion of the investigator would make the subject unsuitable for participation in this long-term study.
* Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnanDeart during the time of study participation.
* Exacerbation History: Subjects who received placebo in MEA115588 and had NO exacerbations during the study.
* Oral Corticosteroid Use: Subjects who received placebo in MEA115575 and were able to discontinue oral corticosteroid therapy by the end of the study.
* Smoking Status: Current smokers
* Previous Significant Protocol Deviation: Subjects who were excluded from the per protocol analysis due to significant protocol deviations in either study MEA115575 or MEA115588.
* Electrocardiogram (ECG) Assessment: A clinically significant ECG abnormality at the exit visit of MEA115661, as determined by the investigator.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/05/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/10/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
339
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - New Lambton
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Bedford Park
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Clayton
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2305 - New Lambton
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Utah
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Buenos Aires
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Mendoza
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Santa Fe
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Bruxelles
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Gent
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Leuven
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Liège
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Alberta
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
British Columbia
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Manitoba
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Ontario
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Quebec
Query!
Country [24]
0
0
Chile
Query!
State/province [24]
0
0
Reg Del Libert Bern Ohiggins
Query!
Country [25]
0
0
Chile
Query!
State/province [25]
0
0
Santiago
Query!
Country [26]
0
0
Chile
Query!
State/province [26]
0
0
Talcahuano
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Brno
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Olomouc
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Praha 4
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Praha 8
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Gières
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Kremlin-Bicêtre
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Lille cedex
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Lyon cedex 04
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Marseille cedex 20
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Montpellier cedex 5
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Nantes cedex 1
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Paris Cedex 18
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Perpignan
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Strasbourg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Bayern
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Brandenburg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Hessen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Niedersachsen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Rheinland-Pfalz
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Schleswig-Holstein
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Berlin
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Hamburg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Magdeburg
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Campania
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Emilia-Romagna
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Liguria
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Puglia
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Umbria
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Veneto
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Chiba
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Fukuoka
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Gunma
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Hokkaido
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Ibaraki
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Kanagawa
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Okinawa
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Osaka
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Tokyo
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Anyang-Si Gyeonggi-do
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Bucheon city, Gyenggi-do
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Cheongju, Chungcheongbuk-do
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Donggu Gwangju
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Seoul
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Suwon-si, Gyeonggi-do
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Amsterdam
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Leeuwarden
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Bialystok
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Krakow
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Chelyabinsk
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Moscow
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Saint-Petersburg
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
St. Petersburg
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Alicante
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Barcelona
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Pozuelo De Alarcón/Madrid
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Kharkiv
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Kiev
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Mykolaiv
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Vinnytsia
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Leicestershire
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Bradford
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Plymouth
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma. This study will enroll a subset of subjects from Study MEA115661 who have demonstrated clear benefit from therapy and who without continuation of mepolizumab therapy are individuals at greatest risk of serious deterioration of their health status. In order to target individuals at greatest risk for serious deterioration of their health status, only subjects from the MEA115661 study with a history of life-threatening or seriously debilitating asthma, will be allowed to participate. Subjects meeting all of the eligibility criteria for the study will be offered the opportunity to consent for this study of up to 128 weeks in length (including the Follow-Up Visit). This study will give opportunity to extend the collection of clinical data for long-term use and further assess the sustainability of efficacy in a population likely to experience significant loss of asthma control and the need for higher doses of systemic steroids if returned to SOC only.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02135692
Query!
Trial related presentations / publications
Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
IPD for this study will be made available via the Clinical Study Data Request site.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
IPD is available via the Clinical Study Data Request site (click on the link provided below)
Query!
Available to whom?
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://clinicalstudydatarequest.com/Posting.aspx?ID=20059
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/92/NCT02135692/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/92/NCT02135692/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02135692